<unk> , sold under the brand name Benlysta, is a human monoclonal antibody that inhibits B-cell activating factor (BAFF), also known as B-lymphocyte stimulator (BLyS). It is approved in the United States, Canada, and the European Union to treat systemic lupus erythematosus (SLE). The most common side effects include bacterial infections, such as bronchitis (infection in the lungs) and infection of the urinary tract (structures that produce or carry urine), diarrhea and nausea (feeling sick). Infections may be more likely in younger children.
Belimumab
Sarilumab
Golimumab
Burosumab
Belatacept
Tofacitinib
Avelumab
Anifrolumab